131 related articles for article (PubMed ID: 10855011)
1. [Should cefminox substitute cefoxitin in infections caused by bacteria susceptible to both drugs?].
Dámaso D; Burillo A; Rogero G; Losada I
Rev Esp Quimioter; 1999 Dec; 12(4):325-31. PubMed ID: 10855011
[TBL] [Abstract][Full Text] [Related]
2. [Should cefminox substitute cefoxitin in infectionscaused by bacteria susceptible to both drugs?].
Dámaso D; Burillo A; Rogero G; Losada I
Rev Esp Quimioter; 1999; 12(4):325-331. PubMed ID: 10878524
[TBL] [Abstract][Full Text] [Related]
3. Cefoxitin: single-agent treatment of mixed aerobic-anaerobic pelvic infections.
Sweet RL; Ledger WJ
Obstet Gynecol; 1979 Aug; 54(2):193-8. PubMed ID: 460753
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro and in vivo activity of cefminox (MT-141), cefotaxime and cefoperazone against gram-negative bacteria.
Watanabe T; Kazuno Y; Hirano F; Inouye S; Nishino T
Drugs Exp Clin Res; 1985; 11(11):781-6. PubMed ID: 3841789
[TBL] [Abstract][Full Text] [Related]
5. [Efficiency of cefmetazole and cefoxitin in the treatment of sepsis caused by gram-negative bacteria].
Noguerado A; García-Monzón C; Martínez MC; Isasia T; Padilla B; Arribas I; Moreno MJ; Jiménez ML
Rev Clin Esp; 1988 Mar; 182(5):250-2. PubMed ID: 3041494
[No Abstract] [Full Text] [Related]
6. Role of cephamycins in obstetrics and gynecology.
Sweet RL
J Reprod Med; 1990 Nov; 35(11 Suppl):1064-9. PubMed ID: 2277374
[TBL] [Abstract][Full Text] [Related]
7. [Surveillance on drug resistance of gram-negative bacilli isolated from hospital acquired infections and community acquired infections (2000 - 2001)].
Li JT; Li Y; Wang J;
Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(12):1035-45. PubMed ID: 12899774
[TBL] [Abstract][Full Text] [Related]
8. Current status of therapy with cefoxitin.
McCloskey RV; Goren RC
Clin Ther; 1980; 3(2):66-79. PubMed ID: 7448845
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
10. Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003-2007.
Guembe M; Cercenado E; Alcalá L; Marín M; Insa R; Bouza E
Rev Esp Quimioter; 2008 Sep; 21(3):166-73. PubMed ID: 18792817
[TBL] [Abstract][Full Text] [Related]
11. Biological and chemotherapeutic studies on three semisynthetic cephamycins.
Uri JV; Actor P; Guarini JR; Phillips L; Pitkin D; Demarinis RM; Weisbach JA
J Antibiot (Tokyo); 1978 Jan; 31(1):82-91. PubMed ID: 627526
[TBL] [Abstract][Full Text] [Related]
12. Cefoxitin and cephamycins: microbiological studies.
Stapley EO; Birnbaum J; Miller AK; Wallick H; Hendlin D; Woodruff HB
Rev Infect Dis; 1979; 1(1):73-89. PubMed ID: 400941
[TBL] [Abstract][Full Text] [Related]
13. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
14. [Prospective and comparative study of cefoxitin and ceftizoxime in appendicitis surgery].
Sanz Villa N; Alvarez Bernaldo de Quirós M; Cortés Gómez MJ; Omeñaca C
An Esp Pediatr; 1997 Sep; 47(3):279-84. PubMed ID: 9499281
[TBL] [Abstract][Full Text] [Related]
15. Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin.
Wilson SE; Boswick JA; Duma RJ; Echols RM; Jemsek JG; Lerner R; Lewis RT; Najem AZ; Press RA; Rittenbury MS
Am J Surg; 1988 May; 155(5A):61-6. PubMed ID: 3287971
[TBL] [Abstract][Full Text] [Related]
16. Cephalosporins: rationale for clinical use.
Molavi A
Am Fam Physician; 1991 Mar; 43(3):937-48. PubMed ID: 2000736
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of cefminox in the treatment of bacterial infections.
Omoto S; Watanabe S
Int J Clin Pharmacol Res; 1990; 10(6):361-8. PubMed ID: 2099361
[TBL] [Abstract][Full Text] [Related]
18. ['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp].
Vay CA; Almuzara MN; Rodríguez CH; Pugliese ML; Lorenzo Barba F; Mattera JC; Famiglietti AM
Rev Argent Microbiol; 2005; 37(1):34-45. PubMed ID: 15991478
[TBL] [Abstract][Full Text] [Related]
19. Cefoxitin: an overview of clinical studies in the United States.
Neu HC
Rev Infect Dis; 1979; 1(1):233-9. PubMed ID: 400937
[TBL] [Abstract][Full Text] [Related]
20. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
